
Myles A Ingram

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2252337/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cost-effectiveness of universal screening for germline BRCA mutations in metastatic pancreatic cancer Journal of Clinical Oncology, 2022, 40, 536-536.	1.6	1
2	Costâ€effectiveness of neoadjuvant <scp>FOLFIRINOX</scp> versus gemcitabine plus nabâ€paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports, 2022, 5, e1565.	1.4	4
3	Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer Journal of Clinical Oncology, 2022, 40, e16268-e16268.	1.6	0
4	Disease Course and Outcomes of COVID-19 Among Hospitalized Patients With Gastrointestinal Manifestations. Clinical Gastroenterology and Hepatology, 2021, 19, 1402-1409.e1.	4.4	28
5	Prevalence of Clostridioides difficile and Other Gastrointestinal Pathogens in Patients with COVID-19. Digestive Diseases and Sciences, 2021, 66, 4398-4405.	2.3	27
6	Prediction of COVID-19 Social Distancing Adherence (SoDA) on the United States county-level. Humanities and Social Sciences Communications, 2021, 8, .	2.9	13
7	Cost-effectiveness analysis of platinum-based chemotherapy treatment options for germline BRCA-mutated locally advanced/borderline resectable pancreatic cancer Journal of Clinical Oncology, 2021, 39, e16246-e16246.	1.6	0
8	Where Have All the Emergencies Gone? The Impact of the COVID-19 Pandemic on Obstetric and Gynecologic Procedures and Consults at a New York City Hospital. Journal of Minimally Invasive Gynecology, 2020, 28, 1411-1419.e1.	0.6	24
9	Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. Journal of Oncology, 2020, 2020, 1-10.	1.3	10
10	Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in locally advanced/borderline resectable pancreatic cancer patients Journal of Clinical Oncology, 2020, 38, e16793-e16793.	1.6	0
11	Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A	1.6	0